HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Digitalization Key To Sustaining COVID-Related Boost To UK Supplements Market

Executive Summary

Thanks to coronavirus-related wellness trends, the UK's vitamins and mineral supplementns market is set to be worth $664m by the end of the year, according to Mintel. But to make sure this increased demand is here to stay, consumer health companies need to leverage the power of digital to help consumers establish long-term supplementation habits into the future. 

You may also be interested in...



UK Says Still No Evidence Vitamin D Prevents Or Treats COVID-19

Yet another rapid review by the UK's NICE finds insufficient evidence to support taking vitamin D to prevent or treat COVID-19. Nevertheless, the UK government is handing out free vitamin D supplements to clinically vulnerable groups in England from Janurary. 

Coronavirus Notebook: UK Begins COVID-19 Vaccine Rollout, Government May Enlist Military Backup

EU passes legislation allowing VAT exemption for coronavirus vaccines to make them more affordable, as two treatments for severe disease and “Long COVID” respectively enter Phase II trials.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150834

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel